Precaution on genome editing bad – targeted gene modifications likely safe
Chan, S. (2020). Quals: Sarah Chan is a Chancellor’s Fellow at the Usher Institute for Population Health Sciences and Informatics, University of Edinburgh. She was educated at the University of Melbourne, Australia, where she completed degrees in biological science and in law, and spent a number of years as a researcher in a molecular biology laboratory before moving to work in the area of science policy and stem cell ethics. In 2005 Sarah took up a Research Fellowship in Bioethics and Law at the Centre for Social Ethics and Policy, University of Manchester, where she also completed a MA in Health Care Ethics and Law and a PhD in Bioethics. From 2009 to 2015 she was Deputy Director of the Institute for Science, Ethics and Innovation, University of Manchester. Her research interests and publications cover areas including the ethics of gene therapy and genetic information, enhancement, research ethics, stem cells, animal ethics, transhumanism, and the ethics of science and innovation.Playing it Safe? Precaution, Risk, and Responsibility in Human Genome Editing. Perspectives in Biology and Medicine 63(1), 111-125. doi:10.1353/pbm.2020.0009. /nfs
This analogy, they argue, relies on misconceived interpretations of evolutionary theory: we should resist the presumption that intentional genetic modification is likely to be more dangerous than “unintentional genetic modification”—that is, the process of mutation, inheritance, and selection that occurs whether we like it or not. It may be that random genetic changes are more likely to be deleterious than beneficial, but this is not necessarily true of targeted modifications designed with some understanding of their likely effects. Moreover, judgments about risk are not absolute but comparative: whether a likely consequence is better than or worse than the alternative. Precaution as a presumption against action assumes that the consequences of doing are probably going to be worse than not-doing. In the case of genome editing for serious disease, it is far from evident that this is so